Advertisement

Immunphänotypisierung von Lungentumoren

Ein Update
  • A. WarthEmail author
  • L. Fink
Übersichten
  • 98 Downloads

Zusammenfassung

Mit der WHO-Klassifikation von 2015 wurde die Anwendung immunhistochemischer Marker in der Diagnostik pulmonaler Tumoren deutlich erweitert. Bislang gab es hierzu jedoch keine weiterführenden Empfehlungen. Erstmals liegen nun von den Autoren der WHO-Klassifikation erarbeitete Empfehlungen diesbezüglich vor, die im Rahmen dieses Artikels beleuchtet werden.

Schlüsselwörter

Lungenkrebs Immunhistochemie Empfehlung Richtlinie 

Immunophenotyping of lung tumors

An update

Abstract

The WHO Classification of Lung Tumors (2015) established the use of immunohistochemical stainings for resection specimens, however, detailed recommendations had been missing. Now, an international expert panel has summarized key questions for daily routine practice and provided recommendations to assist the community in the appropriate use of immunohistochemistry in this context. This article provides an overview of the most important aspects.

Keywords

Lung cancer Immunohistochemistry Recommendation Guideline 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

A. Warth und L. Fink geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Literatur

  1. 1.
    Achcar Rde O, Nikiforova MN, Dacic S et al (2009) Mammalian mastermind like 2 11q21 gene rearrangement in bronchopulmonary mucoepidermoid carcinoma. Hum Pathol 40:854–860CrossRefGoogle Scholar
  2. 2.
    Berg KB, Churg A (2017) GATA3 immunohistochemistry for distinguishing sarcomatoid and desmoplastic mesothelioma from sarcomatoid carcinoma of the lung. Am J Surg Pathol 41:1221–1225CrossRefGoogle Scholar
  3. 3.
    Bishop JA (2013) Unmasking MASC: Bringing to light the unique morphologic, immunohistochemical and genetic features of the newly recognized mammary analogue secretory carcinoma of salivary glands. Head Neck Pathol 7:35–39CrossRefGoogle Scholar
  4. 4.
    Bishop JA, Teruya-Feldstein J, Westra WH et al (2012) p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 25:405–415CrossRefGoogle Scholar
  5. 5.
    Fechner RE, Bentinck BR, Askew JB Jr. (1972) Acinic cell tumor of the lung. A histologic and ultrastructural study. Cancer 29:501–508CrossRefGoogle Scholar
  6. 6.
    Garcia JJ, Jin L, Jackson SB et al (2015) Primary pulmonary hyalinizing clear cell carcinoma of bronchial submucosal gland origin. Hum Pathol 46:471–475CrossRefGoogle Scholar
  7. 7.
    Gruchy JR, Barnes PJ, Dakin Hache KA (2015) CytoLyt(R) fixation and decalcification pretreatments alter antigenicity in normal tissues compared with standard formalin fixation. Appl Immunohistochem Mol Morphol 23:297–302CrossRefGoogle Scholar
  8. 8.
    Harms A, Endris V, Winter H et al (2018) Molecular dissection of large cell carcinomas of the lung with null immunophenotype. Pathology 50:530–535CrossRefGoogle Scholar
  9. 9.
    Harms A, Herpel E, Pfarr N et al (2015) NUT carcinoma of the thorax: Case report and review of the literature. Cancer Treat Res 90:484–491Google Scholar
  10. 10.
    Herpel E, Rieker RJ, Dienemann H et al (2017) SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: Immunohistochemical survey of 316 consecutive specimens. Ann Diagn Pathol 26:47–51CrossRefGoogle Scholar
  11. 11.
    Herth FJ, Bubendorf L, Gutz S et al (2013) Diagnostic and predictive analyses of cytological specimens of non-small cell lung cancer: Strategies and challenges. Pneumologie 67:198–204CrossRefGoogle Scholar
  12. 12.
    Howe MC, Chapman A, Kerr K et al (2005) Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. Histopathology 46:195–201CrossRefGoogle Scholar
  13. 13.
    Huang T, McHugh JB, Berry GJ et al (2018) Primary mammary analogue secretory carcinoma of the lung: A case report. Hum Pathol 74:109–113CrossRefGoogle Scholar
  14. 14.
    Ionescu DN, Treaba D, Gilks CB et al (2007) Nonsmall cell lung carcinoma with neuroendocrine differentiation—An entity of no clinical or prognostic significance. Am J Surg Pathol 31:26–32CrossRefGoogle Scholar
  15. 15.
    Junker K, Buttner R, Langer T et al (2018) Pathological-anatomical diagnosis according to the German lung cancer guideline 2018. Pathologe 39:589–603CrossRefGoogle Scholar
  16. 16.
    Kimbrell HZ, Gustafson KS, Huang M et al (2012) Subclassification of non-small cell lung cancer by cytologic sampling: A logical approach with selective use of immunocytochemistry. Acta Cytol 56:419–424CrossRefGoogle Scholar
  17. 17.
    Kimura N, Hasegawa M, Hiroshima K (2018) SMARCB1/INI1/BAF47− deficient pleural malignant mesothelioma with rhabdoid features. Pathol Int 68:128–132CrossRefGoogle Scholar
  18. 18.
    Klebe S, Swalling A, Jonavicius L et al (2016) An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma. J Clin Pathol 69:136–141CrossRefGoogle Scholar
  19. 19.
    Kossakowski CA, Morresi-Hauf A, Schnabel PA et al (2014) Preparation of cell blocks for lung cancer diagnosis and prediction: Protocol and experience of a high-volume center. Respiration 87:432–438CrossRefGoogle Scholar
  20. 20.
    Krasinskas AM, Chiosea SI, Pal T et al (2014) KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas. Mod Pathol 27:262–270CrossRefGoogle Scholar
  21. 21.
    Kriegsmann M, Harms A, Kazdal D et al (2018) Analysis of the proliferative activity in lung adenocarcinomas with specific driver mutations. Pathol Res Pract 214:408–416CrossRefGoogle Scholar
  22. 22.
    Kriegsmann M, Harms A, Longuespee R et al (2018) Role of conventional immunomarkers, HNF4-alpha and SATB2, in the differential diagnosis of pulmonary and colorectal adenocarcinomas. Histopathology 72:997–1006CrossRefGoogle Scholar
  23. 23.
    Kriegsmann M, Warth A (2016) Ki-67 expression in pulmonary tumors-reply. Transl Lung Cancer Res 5:552–553CrossRefGoogle Scholar
  24. 24.
    Kriegsmann M, Warth A (2016) What is better/reliable, mitosis counting or Ki67/MIB1 staining? Transl Lung Cancer Res 5:543–546CrossRefGoogle Scholar
  25. 25.
    Leduc C, Zhang L, Oz B et al (2016) Thoracic myoepithelial tumors: A pathologic and molecular study of 8 cases with review of the literature. Am J Surg Pathol 40:212–223PubMedPubMedCentralGoogle Scholar
  26. 26.
    Matoso A, Singh K, Jacob R et al (2010) Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl Immunohistochem Mol Morphol 18:142–149CrossRefGoogle Scholar
  27. 27.
    Nguyen CV, Suster S, Moran CA (2009) Pulmonary epithelial-myoepithelial carcinoma: a clinicopathologic and immunohistochemical study of 5 cases. Hum Pathol 40:366–373CrossRefGoogle Scholar
  28. 28.
    Nonaka D (2012) A study of DeltaNp63 expression in lung non-small cell carcinomas. Am J Surg Pathol 36:895–899CrossRefGoogle Scholar
  29. 29.
    Ordonez NG (2012) Value of thyroid transcription factor-1 immunostaining in tumor diagnosis: A review and update. Appl Immunohistochem Mol Morphol 20:429–444CrossRefGoogle Scholar
  30. 30.
    Pelosi G, Rindi G, Travis WD et al (2014) Ki-67 antigen in lung neuroendocrine tumors: Unraveling a role in clinical practice. J Thorac Oncol 9:273–284CrossRefGoogle Scholar
  31. 31.
    Rekhtman N, Kazi S (2015) Nonspecific reactivity of polyclonal napsin a antibody in mucinous adenocarcinomas of various sites: A word of caution. Arch Pathol Lab Med 139:434–436CrossRefGoogle Scholar
  32. 32.
    Rekhtman N, Pietanza CM, Sabari J et al (2018) Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: Napsin A expression and genomic alterations. Mod Pathol 31:111–121CrossRefGoogle Scholar
  33. 33.
    Rindi G, Klersy C, Inzani F et al (2014) Grading the neuroendocrine tumors of the lung: An evidence-based proposal. Endocr Relat Cancer 21:1–16CrossRefGoogle Scholar
  34. 34.
    Ritterhouse LL, Vivero M, Mino-Kenudson M et al (2017) GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas. Mod Pathol 30:1720–1727CrossRefGoogle Scholar
  35. 35.
    Roden AC, Greipp PT, Knutson DL et al (2015) Histopathologic and cytogenetic features of pulmonary adenoid cystic carcinoma. J Thorac Oncol 10:1570–1575CrossRefGoogle Scholar
  36. 36.
    Rosenblatt MB, Lisa JR, Collier F (1967) Primary and metastatic bronciolo-alveolar carcinoma. Dis Chest 52:147–152CrossRefGoogle Scholar
  37. 37.
    Sauter JL, Grogg KL, Vrana JA et al (2016) Young investigator challenge: Validation and optimization of immunohistochemistry protocols for use on cellient cell block specimens. Cancer Cytopathol 124:89–100CrossRefGoogle Scholar
  38. 38.
    Savera AT, Sloman A, Huvos AG et al (2000) Myoepithelial carcinoma of the salivary glands: A clinicopathologic study of 25 patients. Am J Surg Pathol 24:761–774CrossRefGoogle Scholar
  39. 39.
    Smits AJ, Vink A, Tolenaars G et al (2015) Different cutoff values for thyroid transcription factor-1 antibodies in the diagnosis of lung adenocarcinoma. Appl Immunohistochem Mol Morphol 23:416–421CrossRefGoogle Scholar
  40. 40.
    Sterlacci W, Fiegl M, Hilbe W et al (2009) Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: A retrospective study on 405 surgically resected cases. Virchows Arch 455:125–132CrossRefGoogle Scholar
  41. 41.
    Thunnissen E, Borczuk AC, Flieder DB et al (2017) The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An international reproducibility study in a demanding set of cases. J Thorac Oncol 12:334–346CrossRefGoogle Scholar
  42. 42.
    Tran L, Mattsson JS, Nodin B et al (2016) Various antibody clones of napsin A, thyroid transcription factor 1, and p40 and comparisons with cytokeratin 5 and p63 in histopathologic diagnostics of non-small cell lung carcinoma. Appl Immunohistochem Mol Morphol 24:648–659CrossRefGoogle Scholar
  43. 43.
    Vidarsdottir H, Tran L, Nodin B et al (2018) Comparison of three different TTF-1 clones in resected primary lung cancer and epithelial pulmonary metastases. Am J Clin Pathol 150:533–544CrossRefGoogle Scholar
  44. 44.
    Warth A, Bubendorf L, Gutz S et al (2013) Molecular pathological diagnosis in cytopathology of non-small-cell lung cancer. Standardization of specimen processing. Pathologe 34:310–317CrossRefGoogle Scholar
  45. 45.
    Warth A, Cortis J, Soltermann A et al (2014) Tumour cell proliferation (Ki-67) in non-small cell lung cancer: A critical reappraisal of its prognostic role. Br J Cancer 111:1222–1229CrossRefGoogle Scholar
  46. 46.
    Warth A, Fink L, Fisseler-Eckhoff A et al (2013) Interobserver agreement of proliferation index (Ki-67) outperforms mitotic count in pulmonary carcinoids. Virchows Arch 462:507–513CrossRefGoogle Scholar
  47. 47.
    Warth A, Muley T, Herpel E et al (2012) Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Histopathology 61:1017–1025CrossRefGoogle Scholar
  48. 48.
    Yatabe Y, Dacic S, Borczuk AC et al (2019) Best practices recommendations for diagnostic Immunohistochemistry in lung cancer. J Thorac Oncol 14(3):377–407CrossRefGoogle Scholar
  49. 49.
    Ye B, Cappel J, Findeis-Hosey J et al (2016) hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors. Hum Pathol 48:142–147CrossRefGoogle Scholar
  50. 50.
    Yoshida A, Kobayashi E, Kubo T et al (2017) Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. Mod Pathol 30:797–809CrossRefGoogle Scholar
  51. 51.
    Zahel T, Krysa S, Herpel E et al (2012) Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach. Virchows Arch 460:299–308CrossRefGoogle Scholar
  52. 52.
    Zhang C, Schmidt LA, Hatanaka K et al (2014) Evaluation of napsin A, TTF-1, p63, p40, and CK5/6 immunohistochemical stains in pulmonary neuroendocrine tumors. Am J Clin Pathol 142:320–324CrossRefGoogle Scholar
  53. 53.
    Zhao W, Wang H, Peng Y et al (2014) DeltaNp63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens. Int J Clin Exp Pathol 7:4247–4253PubMedPubMedCentralGoogle Scholar
  54. 54.
    Zhou F, Moreira AL (2016) Lung carcinoma predictive biomarker testing by Immunoperoxidase stains in cytology and small biopsy specimens: Advantages and limitations. Arch Pathol Lab Med 140:1331–1337CrossRefGoogle Scholar
  55. 55.
    Zhu S, Schuerch C, Hunt J (2015) Review and updates of immunohistochemistry in selected salivary gland and head and neck tumors. Arch Pathol Lab Med 139:55–66CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Institut für Pathologie, Zytopathologie und MolekularpathologieMVZ ÜGP Gießen/Wetzlar/LimburgWetzlarDeutschland

Personalised recommendations